In-depth phenotyping for clinical stratification of Gaucher disease.
Cohort
Disease-modifying therapies
Enzyme replacement therapy
GAUCHERITE
Gaucher disease
Substrate reduction therapy
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
14 10 2021
14 10 2021
Historique:
received:
22
05
2021
accepted:
19
09
2021
entrez:
15
10
2021
pubmed:
16
10
2021
medline:
3
11
2021
Statut:
epublish
Résumé
The Gaucher Investigative Therapy Evaluation is a national clinical cohort of 250 patients aged 5-87 years with Gaucher disease in the United Kingdom-an ultra-rare genetic disorder. To inform clinical decision-making and improve pathophysiological understanding, we characterized the course of Gaucher disease and explored the influence of costly innovative medication and other interventions. Retrospective and prospective clinical, laboratory and radiological information including molecular analysis of the GBA1 gene and comprising > 2500 variables were collected systematically into a relational database with banking of collated biological samples in a central bioresource. Data for deep phenotyping and life-quality evaluation, including skeletal, visceral, haematological and neurological manifestations were recorded for a median of 17.3 years; the skeletal and neurological manifestations are the main focus of this study. At baseline, 223 of the 250 patients were classified as type 1 Gaucher disease. Skeletal manifestations occurred in most patients in the cohort (131 of 201 specifically reported bone pain). Symptomatic osteonecrosis and fragility fractures occurred respectively in 76 and 37 of all 250 patients and the first osseous events occurred significantly earlier in those with neuronopathic disease. Intensive phenotyping in a subgroup of 40 patients originally considered to have only systemic features, revealed neurological involvement in 18: two had Parkinson disease and 16 had clinical signs compatible with neuronopathic Gaucher disease-indicating a greater than expected prevalence of neurological features. Analysis of longitudinal real-world data enabled Gaucher disease to be stratified with respect to advanced therapies and splenectomy. Splenectomy was associated with an increased hazard of fragility fractures, in addition to osteonecrosis and orthopaedic surgery; there were marked gender differences in fracture risk over time since splenectomy. Skeletal disease was a heavy burden of illness, especially where access to specific therapy was delayed and in patients requiring orthopaedic surgery. Gaucher disease has been explored using real-world data obtained in an era of therapeutic transformation. Introduction of advanced therapies and repeated longitudinal measures enabled this heterogeneous condition to be stratified into obvious clinical endotypes. The study reveals diverse and changing phenotypic manifestations with systemic, skeletal and neurological disease as inter-related sources of disability.
Sections du résumé
BACKGROUND
The Gaucher Investigative Therapy Evaluation is a national clinical cohort of 250 patients aged 5-87 years with Gaucher disease in the United Kingdom-an ultra-rare genetic disorder. To inform clinical decision-making and improve pathophysiological understanding, we characterized the course of Gaucher disease and explored the influence of costly innovative medication and other interventions. Retrospective and prospective clinical, laboratory and radiological information including molecular analysis of the GBA1 gene and comprising > 2500 variables were collected systematically into a relational database with banking of collated biological samples in a central bioresource. Data for deep phenotyping and life-quality evaluation, including skeletal, visceral, haematological and neurological manifestations were recorded for a median of 17.3 years; the skeletal and neurological manifestations are the main focus of this study.
RESULTS
At baseline, 223 of the 250 patients were classified as type 1 Gaucher disease. Skeletal manifestations occurred in most patients in the cohort (131 of 201 specifically reported bone pain). Symptomatic osteonecrosis and fragility fractures occurred respectively in 76 and 37 of all 250 patients and the first osseous events occurred significantly earlier in those with neuronopathic disease. Intensive phenotyping in a subgroup of 40 patients originally considered to have only systemic features, revealed neurological involvement in 18: two had Parkinson disease and 16 had clinical signs compatible with neuronopathic Gaucher disease-indicating a greater than expected prevalence of neurological features. Analysis of longitudinal real-world data enabled Gaucher disease to be stratified with respect to advanced therapies and splenectomy. Splenectomy was associated with an increased hazard of fragility fractures, in addition to osteonecrosis and orthopaedic surgery; there were marked gender differences in fracture risk over time since splenectomy. Skeletal disease was a heavy burden of illness, especially where access to specific therapy was delayed and in patients requiring orthopaedic surgery.
CONCLUSION
Gaucher disease has been explored using real-world data obtained in an era of therapeutic transformation. Introduction of advanced therapies and repeated longitudinal measures enabled this heterogeneous condition to be stratified into obvious clinical endotypes. The study reveals diverse and changing phenotypic manifestations with systemic, skeletal and neurological disease as inter-related sources of disability.
Identifiants
pubmed: 34649574
doi: 10.1186/s13023-021-02034-6
pii: 10.1186/s13023-021-02034-6
pmc: PMC8515714
doi:
Substances chimiques
Glucosylceramidase
EC 3.2.1.45
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
431Subventions
Organisme : Medical Research Council
ID : MC_UU_00002/2
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/K015338/1
Pays : United Kingdom
Investigateurs
T M Cox
(TM)
F M Platt
(FM)
S Banka
(S)
A Chakrapani
(A)
P B Deegan
(PB)
T Geberhiwot
(T)
D A Hughes
(DA)
S Jones
(S)
R H Lachmann
(RH)
S Santra
(S)
R Sharma
(R)
A Vellodi
(A)
Informations de copyright
© 2021. The Author(s).
Références
Blood. 2013 Jan 17;121(3):546-55
pubmed: 23212518
J Inherit Metab Dis. 2011 Oct;34(5):1053-9
pubmed: 21626202
J Inherit Metab Dis. 2008 Jun;31(3):337-49
pubmed: 18404411
QJM. 2004 Apr;97(4):199-204
pubmed: 15028849
Medicine (Baltimore). 2011 Jan;90(1):52-60
pubmed: 21200186
J Bone Miner Res. 2019 Jun;34(6):996-1013
pubmed: 31233632
Crit Rev Oncog. 2013;18(3):163-75
pubmed: 23510062
Mol Genet Metab. 2004 Jul;82(3):192-207
pubmed: 15234332
Blood Cells Mol Dis. 2005 May-Jun;34(3):197-200
pubmed: 15885601
JAMA. 2015 Feb 17;313(7):695-706
pubmed: 25688781
Am J Hematol. 2011 Jan;86(1):110-5
pubmed: 21080341
Am J Hematol. 2010 May;85(5):340-5
pubmed: 20425796
Acta Neuropathol. 1984;65(2):99-109
pubmed: 6524300
J Inherit Metab Dis. 2007 Oct;30(5):768-82
pubmed: 17876722
Ann Neurol. 1986 Aug;20(2):223-30
pubmed: 3752966
Arch Intern Med. 2000 Oct 9;160(18):2835-43
pubmed: 11025794
Am J Hematol. 2018 Feb;93(2):205-212
pubmed: 29090476
Cancers (Basel). 2020 Feb 18;12(2):
pubmed: 32085512
Blood. 2017 Apr 27;129(17):2375-2383
pubmed: 28167660
Br J Radiol. 2012 Jul;85(1015):905-9
pubmed: 22010032
Orphanet J Rare Dis. 2012 Oct 09;7:77
pubmed: 23046562
J Inherit Metab Dis. 2020 Sep;43(5):1056-1059
pubmed: 32242941
Eur J Haematol. 2005 Sep;75(3):252-8
pubmed: 16104883
Genet Med. 2010 Jan;12(1):44-51
pubmed: 20027115
Am J Physiol Renal Physiol. 2015 Dec 15;309(12):F996-9
pubmed: 26447223
Hematology. 2017 Mar;22(2):65-73
pubmed: 27762169
Semin Hematol. 2004 Oct;41(4 Suppl 5):4-14
pubmed: 15468045
Osteoporos Int. 1999;9(5):379-93
pubmed: 10550456
Int J Mol Sci. 2017 Feb 17;18(2):
pubmed: 28218669
J Bone Miner Res. 2012 Aug;27(8):1839-48
pubmed: 22692814
Front Neurol. 2018 Jan 15;8:711
pubmed: 29379464
Orphanet J Rare Dis. 2020 Dec 17;15(1):349
pubmed: 33334373
Biochem Biophys Res Commun. 1965 Jan 18;18:221-5
pubmed: 14282020
Baillieres Clin Haematol. 1997 Dec;10(4):691-709
pubmed: 9497858
Am J Surg. 1991 Jan;161(1):69-75
pubmed: 1987860
QJM. 2000 Apr;93(4):237-44
pubmed: 10787452
Biologics. 2010 Dec 06;4:299-313
pubmed: 21209725
Brain. 2002 Jul;125(Pt 7):1570-82
pubmed: 12077006
Am J Hematol. 2019 Jan;94(1):29-38
pubmed: 30264864
Proc Natl Acad Sci U S A. 2017 Apr 18;114(16):E3285-E3294
pubmed: 28373578
N Engl J Med. 1997 Sep 11;337(11):762-9
pubmed: 9287233
J Inherit Metab Dis. 2001;24 Suppl 2:106-21; discussion 87-8
pubmed: 11758671
Prog Clin Biol Res. 1982;95:1-30
pubmed: 6750651
J Clin Invest. 2020 Sep 1;130(9):4811-4830
pubmed: 32773408
Lancet. 1987 May 16;1(8542):1111-5
pubmed: 2883444
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Crit Rev Oncog. 2013;18(3):235-46
pubmed: 23510066
Orphanet J Rare Dis. 2021 Feb 18;16(1):92
pubmed: 33602299
Drug Des Devel Ther. 2012;6:81-106
pubmed: 22563238
Br J Haematol. 2009 Nov;147(4):561-70
pubmed: 19732054
Ann N Y Acad Sci. 2009 May;1164:461-7
pubmed: 19645949
Curr Rheumatol Rep. 2000 Apr;2(2):175-80
pubmed: 11123056
Mol Genet Metab. 2011 Feb;102(2):226-8
pubmed: 21036086
Am J Hematol. 2020 Sep;95(9):1038-1046
pubmed: 32438452
Hum Mutat. 2012 May;33(5):777-80
pubmed: 22504886
Br J Radiol. 1987 Dec;60(720):1189-95
pubmed: 3319001
Baillieres Clin Haematol. 1997 Dec;10(4):657-89
pubmed: 9497857
Blood Adv. 2019 May 14;3(9):1476-1488
pubmed: 31072833
Medicine (Baltimore). 1992 Nov;71(6):337-53
pubmed: 1435229
Clin Genet. 2015 Oct;88(4):391-5
pubmed: 25287185
N Engl J Med. 1991 May 23;324(21):1464-70
pubmed: 2023606
Lancet. 2008 Oct 4;372(9645):1263-71
pubmed: 19094956
Hum Genet. 1999 Jul-Aug;105(1-2):120-6
pubmed: 10480365
Blood Cells Mol Dis. 2011 Jan 15;46(1):66-72
pubmed: 21112800
Mol Genet Metab. 2002 Sep-Oct;77(1-2):91-8
pubmed: 12359135
Am J Hematol. 2017 Nov;92(11):1170-1176
pubmed: 28762527
Orphanet J Rare Dis. 2012 Mar 19;7:17
pubmed: 22429443
Blood Cells Mol Dis. 2011 Jan 15;46(1):39-41
pubmed: 21056933
J Bone Miner Res. 1996 Nov;11(11):1801-7
pubmed: 8915789
Curr Protoc Hum Genet. 2016 Jul 01;90:7.13.1-7.13.19
pubmed: 27367167
Lancet. 2000 Apr 29;355(9214):1481-5
pubmed: 10801168
Mol Genet Metab Rep. 2017 Jul 11;13:1-2
pubmed: 28736718
Hum Genet. 1993 Nov;92(5):513-5
pubmed: 8244344